Attached files

file filename
10-K - 10-K - TETRALOGIC PHARMACEUTICALS Corpa2218960z10-k.htm
EX-23.1 - EX-23.1 - TETRALOGIC PHARMACEUTICALS Corpa2218960zex-23_1.htm
EX-31.2 - EX-31.2 - TETRALOGIC PHARMACEUTICALS Corpa2218960zex-31_2.htm
EX-31.1 - EX-31.1 - TETRALOGIC PHARMACEUTICALS Corpa2218960zex-31_1.htm
EX-32.2 - EX-32.2 - TETRALOGIC PHARMACEUTICALS Corpa2218960zex-32_2.htm

QuickLinks -- Click here to rapidly navigate through this document


Exhibit 32.1

Statement of Chief Executive Officer
Pursuant to Section 1350 of Title 18 of the United States Code

        Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, J. Kevin Buchi, the President and Chief Executive Officer of TetraLogic Pharmaceuticals Corporation (the "Company"), hereby certifies that based on the undersigned's knowledge:

    1)
    The Company's annual report on Form 10-K for the period ended December 31, 2013 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

    2)
    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 19, 2014   /s/ J. KEVIN BUCHI

J. Kevin Buchi
President and Chief Executive Officer



QuickLinks

Statement of Chief Executive Officer Pursuant to Section 1350 of Title 18 of the United States Code